HC Wainwright Comments on ImmunityBio Q1 Earnings

ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for ImmunityBio in a research report issued to clients and investors on Thursday, March 6th. HC Wainwright analyst A. Maldonado anticipates that the company will post earnings per share of ($0.12) for the quarter. HC Wainwright currently has a "Buy" rating and a $8.00 price target on the stock. The consensus estimate for ImmunityBio's current full-year earnings is ($0.92) per share. HC Wainwright also issued estimates for ImmunityBio's Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.11) EPS, Q4 2025 earnings at ($0.10) EPS, FY2025 earnings at ($0.45) EPS, FY2026 earnings at ($0.36) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at $0.03 EPS and FY2029 earnings at $0.29 EPS.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last released its earnings results on Monday, March 3rd. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.11. The company had revenue of $7.55 million during the quarter, compared to analysts' expectations of $8.74 million.

A number of other research firms also recently commented on IBRX. BTIG Research began coverage on ImmunityBio in a research report on Friday, January 10th. They issued a "buy" rating and a $6.00 target price on the stock. D. Boral Capital reissued a "buy" rating and issued a $30.00 target price on shares of ImmunityBio in a report on Thursday. One analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $12.19.

Remove Ads

ImmunityBio Stock Up 1.0 %

IBRX stock traded up $0.03 during mid-day trading on Monday, hitting $2.90. The company had a trading volume of 4,254,281 shares, compared to its average volume of 6,174,018. The company has a 50-day moving average price of $3.07 and a 200 day moving average price of $3.67. ImmunityBio has a 12-month low of $2.28 and a 12-month high of $10.53. The company has a market capitalization of $2.47 billion, a price-to-earnings ratio of -3.15 and a beta of 0.82.

Hedge Funds Weigh In On ImmunityBio

Several institutional investors and hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP increased its position in shares of ImmunityBio by 290.3% in the 3rd quarter. GSA Capital Partners LLP now owns 107,985 shares of the company's stock valued at $402,000 after acquiring an additional 80,318 shares during the period. Intech Investment Management LLC acquired a new stake in shares of ImmunityBio during the third quarter worth about $253,000. Charles Schwab Investment Management Inc. increased its holdings in ImmunityBio by 2.4% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,265,981 shares of the company's stock worth $4,709,000 after buying an additional 29,665 shares during the period. Advantage Alpha Capital Partners LP purchased a new position in ImmunityBio during the 3rd quarter worth approximately $257,000. Finally, Quantbot Technologies LP acquired a new stake in shares of ImmunityBio in the third quarter worth $143,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.